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ABSTRACT Fibril deposit formation of amyloid b-protein (Ab) in the brain is a hallmark of Alzheimer’s disease (AD). Increasing
evidence suggests that toxicity is linked to diffusible Ab oligomers, which have been found in soluble brain extracts of
AD patients, rather than to insoluble ﬁbers. Here we report a study of the toxicity of two distinct forms of recombinant Ab small
oligomers and ﬁbrillar aggregates to simulate the action of diffusible Ab oligomers and amyloid plaques on neuronal cells.
Different techniques, including dynamic light scattering, ﬂuorescence, and scanning electron microscopy, have been used to
characterize the two forms of Ab. Under similar conditions and comparable incubation times in neuroblastoma LAN5 cell cultures,
oligomeric species obtained from Ab peptide are more toxic than ﬁbrillar aggregates. Both oligomers and aggregates are able to
induce neurodegeneration by apoptosis activation, as demonstrated by TUNEL assay and Hoechst staining assays. Moreover,
we show that aggregates induce apoptosis by caspase 8 activation (extrinsic pathway), whereas oligomers induce apoptosis
principally by caspase 9 activation (intrinsic pathway). These results are conﬁrmed by cytochrome c release, almost exclusively
detected in the cytosolic fraction of LAN5 cells treated with oligomers. These ﬁndings indicate an active and direct interaction
between oligomers and the cellular membrane, and are consistent with internalization of the oligomeric species into the cytosol.
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Alzheimer’s disease (AD) is the most common form of senile
dementia and is characterized by a progressive neuronal loss
causing memory deficits, cognitive impairment, disorienta-
tion, and language problems. Despite intensive research,
no effective therapy for AD is currently available. The histo-
pathological hallmarks for the disease are senile plaques and
neurofibrillar tangles, which cause synaptic dysfunction with
subsequent neuronal death, especially in the neurocortical
regions involved in memory and motor processing (1–3).
Senile plaques form in the extracellular space and consist
of a proteinaceous core composed mainly of amyloid
b (Ab)-peptides. Neurofibrillar tangles are formed by
neuronal intracellular deposition of the microtubule-
associated Tau protein (4). The extracellular Ab deposits
found in patients with AD contain ordered aggregates called
amyloid fibrils. The Ab-peptides, which exist as distinct
peptides 39–42 amino acids long, are a product of the
sequential g- and b-secretase proteolytic cleavage of the
amyloid precursor protein (APP) (5). APP is a transmem-
brane protein of unknown function that is expressed in the
heart, kidneys, lungs, spleen, intestine, and brain (6).
In vitro, the more pathological Ab-peptide form, Ab42,
has a high tendency to polymerize and make fibrils, convert-
ing its conformation to a b-rich structure (7). Small oligo-
mers have also been found in the intracellular environment
and the cerebrospinal fluid of AD patients (8). This evidence,
together with the low correlation between brain cell damage
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oligomers’’ rather than mature amyloid fibrils are the early
pathogenic agents in AD (9–14).
In vitro, Ab42 forms fibrils that are similar to those found
in AD plaques. Depending on the pH conditions, it is
possible to obtain samples that contain mainly small oligo-
mers or larger aggregates (15). The structural features of
fibrillar aggregates formed at pH 3.1 at the late stage of the
Ab40 aggregation process have been described in a model
obtained with a combination of different scattering tech-
niques (16). Using a recombinant Ab42 peptide (rAb42)
that presents biophysics and immunological properties
comparable to the natural peptide (17), we recently demon-
strated that, under physiological pH conditions, rAb42
forms small oligomers, whereas at acidic pH large fibrillar
aggregates are formed. Previous toxicity assays using Para-
centrotus lividus embryos as a eukaryotic model system
demonstrated a loss of embryo vitality under incubation
both with oligomers and large aggregates, with a greater
effect observed for the former species (17). In the study
presented here, we investigated the toxicity produced by
small oligomers prepared at physiological pH, and fibrillar
aggregates kept in an acidic solution at T ¼ 37C for
4 days, in a more complex mammalian cell culture, such as
human neuroblastoma LAN5 cells. The possibility of using
in vitro oligomers or larger aggregates formed starting with
the same recombinant peptide allowed us to simulate the
pathophysiological effects that occur in vivo. The molecular
species obtained under different conditions and treatments
were characterized by light scattering after dilution in
RPMI to ascertain that they did not aggregate and/or dissolve
doi: 10.1016/j.bpj.2008.11.056
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of oligomers and fibrillar aggregates on the cellular vitality
was detected, with enhanced degeneration and cell death
caused by the small oligomers. Moreover, we analyzed
which cellular mechanism was involved in the degenerative
process by discriminating two different apoptotic pathways
through the activation of two different caspases. Our results
show that the preformed fibrillar aggregates activate only the
extrinsic apoptotic pathway (caspase 8). Remaining on the
exterior of the cell, they could macroscopically obstruct
the membrane functional space. Conversely, the oligomers
activate mainly the intrinsic degenerative pathway (caspase
9). This different action suggests that the oligomers can either
enter into the cell by a mechanism that is not yet understood
or interact with the cellular membrane. Both mechanisms
could involve some membrane receptors or the well-known
ability of the Ab-peptide to form membrane pores.
MATERIALS AND METHODS
Immunoblot
Isolation and purification of rAb42 were performed as previously described
(17). rAb42 (10 ng) dissolved in 0.01 M Tris-HCl buffer, pH 7.2, or in 0.1 M
Na-citrate buffer, pH 3.1, was electrophoretically separated using 4–12%
gradient gel (NuPAGE; Invitrogen, Carlsbad, CA) and transferred onto nitro-
cellulose filters for immunoblotting. After blocking in 3% BSA in TBST, the
Western blot was incubated with anti-His HRP conjugate (1:5000; Pierce,
Appleton, WI), recognizing the polyhistidine tag (6His) linked at the NH2
terminus of the rAb42 peptide (17). Primary antibodies were directly
detected using the ECL chemiluminescence kit (Amersham Biosciences,
Buckinghamshire, UK) according to the manufacturer’s instructions.
Thioﬂavin T staining
Recombinant Ab42 was dissolved at pH 3.1 and pH 7.2 at a concentration
of 340 mM and incubated at 37C. Aliquots were taken immediately after
dissolution (time 0) and after 24, 48, 72 and 96 h of incubation and stained,
adding thioflavin T (ThT) at a final concentration of 70 mM, and applied to
microscope slides. The presence of large fibrillar aggregates with dimen-
sions in the range of micrometers was visualized with the fluorescence optics
of an Axio Scope 2 microscope (Zeiss, Oberkochen, Germany). The images
were captured using an AxioCam digital camera interfaced with a computer.
Preparation and characterization of rAb42
oligomers and ﬁbrillar aggregates
The preliminary treatment with trifluoroacetic acid (TFA) has been reported
elsewhere (17). To obtain small oligomers, the powder of rAb42 was
dissolved in 0.01 M Tris-HCl buffer, pH 7.2. To obtain large fibrillar aggre-
gates, rAb42 was dissolved in 0.1 M Na-citrate buffer, pH 3.1, with
a concentration of ~300 mM and held at T ¼ 37C for 4 days. In the former
case, the solution was readily characterized by dynamic light scattering
(DLS) at T ¼ 15C. In the latter case, the solution at acid pH was also char-
acterized by DLS at T¼ 15C after 4 days incubation at T¼ 37C. Solutions
at pH 7.2 and pH 3.1 were characterized just after dissolution by Western
blot to confirm a high population of oligomeric species and larger aggre-
gates, respectively. The aggregates’ growth at pH 3.1 was further monitored
during the incubation at T¼ 37C by fluorescence microscopy on aliquots of
solution stained with ThT. After 4 days incubation, the sample diluted up to
3.4 mM was dried and scanning electron microscopy (SEM) was performed
to determine the aggregates’ morphology.To investigate the effect of the dilution in the cellular environment, both
small oligomers prepared at physiological pH and large fibrillar aggregates
made at acidic pH were diluted in RPMI without phenol red to 20 mM. In situ
static light scattering (SLS) and dynamic light scattering (DLS) by both solu-
tions, held at T ¼ 37C, were monitored for 4 h to assess the effect of the
dilution in RPMI and on the temporal evolution of the samples after dilution.
Sample concentration was determined by measuring the UV absorption,
using 3280nm ¼ 1390 M1 cm1.
Static and dynamic light scattering
The cuvette was placed in a thermostatically controlled cell compartment of
a Brookhaven Instrument BI200-SM goniometer equipped with a 100 mW
solid-state laser at l¼ 532 nm. Temperature was thermostatically controlled
by a circulating bath with a tolerance within 0.05C. Scattered light intensity
at q ¼ 90 (q ¼ 4p
l
sinq
2
¼ 22:3mm1), I90(t), and its time autocorrelation
function, g2(t), were measured simultaneously by using a Brookhaven
BI-9000 correlator. The Rayleigh ratio R90 , measured after dilution in
RPMI, was used to estimate the weight-averaged molecular mass Mw of
the samples prepared from the solution at pH 3.1 and pH 7.2. In fact
R90 ¼ KcMwPð90 Þ, where c is the protein weight concentration, Pð90 Þ
is the form factor, and K is a constant that depends, in addition to the
experimental setup, on the refraction index of the solution n, the laser
wavelength l, and the derivative dn/dc (taken 0.18 cm3g1) (18). Absolute
scale was obtained by normalization with respect to toluene, whose Rayleigh
ratio at 532 nm was taken at 28  106 cm1. Autocorrelation functions
g2(t) were analyzed using a smoothing constrained regularization
method (19) to obtain the distribution P(D) of the apparent diffusion
coefficients D: g2ðtÞ ¼ 1 þ Bj
R
PðDÞeDq2 tdDj2, where q is the scattering
vector defined as q ¼ 4pn
l0
sinq
2
. In this equation, q is the scattering angle
and B is a factor depending on the instrumental setup (19). Assuming the
Stokes Einstein relation, we can express the apparent diffusion coefficient
as a function of the z-averaged hydrodynamic radius Rh: D ¼ kT6phRh, where
k is the Boltzmann constant, T is the absolute temperature, and h is the
solvent viscosity. Thus we obtain the distribution P(Rh) of the z-averaged
hydrodynamic radius.
Scanning electron microscopy
A scanning electron microscope (XL-30; Philips, Best, The Netherlands)
was used to evaluate the size and morphology of the rAb42 aggregates,
formed at pH 3.1 after incubation at 37C for 96 h. The sample (3.4 mM)
was deposited on a carbon film and dried under vacuum at room tempera-
ture. Before the SEM analysis, the dried sample was gold-coated, fixed
into a sample holder, and placed in the vacuum chamber of the microscope.
Cell cultures and rAb42 treatment
LAN5 human neuroblastoma cell lines were plated onto 96-well plates at
a density of 3  104 per well and cultured with RPMI 1640 medium
(CELBIO, Milan, Italy) supplemented with 10% fetal bovine serum (FBS;
GIBCO, Auckland, New Zealand) and 1% antibiotics (50 m/mL penicillin
and 50 mg/mL streptomycin) and antimycotics (Sigma). The cells were
maintained in humidified 5% CO2 atmosphere at 37
C and treated with
increasing amounts (3.75, 7.5 15, and 30 mM) of recombinant Ab42 (rAb42)
in oligomer and aggregate forms (15). For the time-dependence experiment,
the 15 mM concentration was used. Depending on the experiment, the
peptides (oligomers/aggregates) were incubated at 37C for 4 or 5 h, or
for 5–24 h. The treated cultured cells and the controls were morphologically
analyzed by microscopy inspection or used for specific assays. As controls
we used untreated cells or cultured cells with buffer (pH 3.1, pH 7.2) in the
concentration and volume utilized to dissolve rAb42.
Immunohistochemistry
LAN5 cells were cultured on slides without or with 15 mM of rAb42 oligo-
mers for 24 h. After washing in PBS (137 mM NaCl, 2.7 mM KCl, 8 mMBiophysical Journal 96(10) 4200–4211
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different structural species. (A) Western blot of rAb42
immediately after dissolution at pH 7.2 (pH 7), and pH
3.1 (pH 3) incubated with anti-His. On the right, molecular
weight standards are indicated. (B) Kinetics of fibrillar
aggregates formation of rAb42 dissolved at pH 3.1. Stain-
ing with ThT at different times of incubation at T ¼ 37C.
Fluorescence images of representative areas of the observa-
tion field, immediately after dissolution (time 0) and after
48 (48 h), 72 (72 h) and 96 h (96 h) of incubation at
T ¼ 37C. Bar: 20 mm.Na2PO4, pH 7.4), the cells were fixed in freshly prepared 4% paraformalde-
hyde in PBS for 30 min and kept at 4C. After three washes in PBS, the slides
were incubated for 1 h with 5% bovine serum albumin/PBS. Then the cultures
were incubated with human anti-Ab (1:200; Santa Cruz Biotechnology, Santa
Cruz, CA) or anti-His (Penta.His Alexa fluor conjugate, 1:100; QIAGEN,
Hiden, Germany) antibodies at 4C overnight. After three washes in TBS
(PBS, 2% Triton X-100) the samples treated with anti-Ab were incubated
with anti-mouse Cy3-conjugate secondary antibody (1:300), whereas the
samples treated with anti-His were directly detected. Fluorescent or light field
images were observed with an Axio Scope 2 microscope (Zeiss) and captured
with an AxioCam digital camera (Zeiss) interfaced with a computer.
Cytotoxic assay
Cell viability was measured by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfopheyl)2H-tetrazolium; Promega, Madi-
son, WI) assay according to the manufacturer’s instructions. After treatment
of the cells, 20 mL of the MTS solution were added to each well and the
incubation was continued for 4 h at 37C, 5% CO2. The absorbance was
read at 490 nm on a microplate reader (Wallac Victor 2 1420 multilabel
counter; PerkinElmer, Waltham, MA). The absorbance of a blank RPMI
sample was subtracted from all the absorption measurements corresponding
to the different samples. The caspase inhibitor assay was performed with
Z-VAD-FMK (50 mM; Promega).
Apoptosis assays
A terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay (Promega) was performed according to the manufacturer’s instruc-
tions. Briefly, cells in oligomer or aggregate form were treated with
20 mM rAb42 for 5 h and then fixed with 4% paraformaldehyde in PBS
for 30 min. They were then washed with PBS permeabilized with 0.2%
Triton X-100 in PBS for 5 min, rinsed with PBS, and incubated with a
TUNEL reaction mixture (enzyme and nucleotides) in a humidified atmo-
sphere at 37C for 1 h. Staining was obtained by using a peroxidase
substrate, hydrogen peroxide, and the stable chromogen diaminobenzidine
(DAB). After these incubations, the samples were rinsed three times with
PBS and analyzed under a Zeiss Axio Scope microscope. For nuclear stain-
ing, the fixed cells were incubated in Hoechst 33258 (5 mg/mL) for 20 min.
Nuclear morphology was analyzed by microscopic inspection using
a Leica DHL fluorescent microscope at excitation/emission wavelengths
of 350/450 nm.
Caspase assays
Caspase-8, 9, 3 activities in cells were measured with the use of commer-
cially available luminescent assays (caspase-Glo8, caspase-Glo 9, and
Biophysical Journal 96(10) 4200–4211caspase-Glo 3/7 assay systems; Promega). LAN5 cells were treated with
20 mM oligomers or aggregates or untreated for 4 h. Caspase reagent specific
for each kit was added directly to the cells in white 96-well plates, and after
mixing were incubated for 15–30 min. Luminescence was recorded with
a Wallac Victor 2 1420 multilabel counter (PerkinElmer) apparatus. The
caspase activator assay was performed with 50 mM vinblastine (Sigma, St.
Louis, MO), and the caspase inhibitor assay was carried out with 50 mM
Z-VAD-FMK (Promega). The luminescence of a blank RPMI sample was
subtracted from all the luminescence measurements corresponding to the
different samples.
Cytochrome c release assay
LAN5 cells treated separately with oligomers or fibrillar aggregates were har-
vested. Cytosol and mitochondria fractions were prepared with the use of a
mitochondria isolation kit (Pierce) according to the manufacturer’s instruc-
tions. Lysates of both the fractions and controls were separated by 4–20%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE;
(Cambrex, Rutherford, NJ) and the Western blot was incubated with
1:1000 diluted anti-cytochrome c (Cell Signaling Technology, Beverly, MA).
Statistical analysis
All experiments were repeated three times. Each experiment was performed
in triplicate. Since the values of the pH 3 and pH 7 control buffers were
very similar to those of the untreated cells, to facilitate the analysis we
used the untreated cells to normalize the values of treated cells. The results
are presented as mean  standard deviation (SD).
RESULTS
Different pH values mediate rAb42 aggregation
differently
To obtain direct evidence that solutions of rAb42 at two
different pH values (7.2 and 3.1) contain different structural
species (small oligomers or larger aggregates, respectively),
an aliquot of the samples, immediately after dissolution in
the different conditions, was loaded on a SDS PAGE. After
running, the gel was transferred to nitrocellulose and the
filter was incubated with anti-His. As shown in Fig. 1 A,
we were able to determine by the molecular weight of the de-
tected bands that monomer or small oligomers were present
in the sample dissolved at pH 7.2, whereas larger aggregates
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30-mer) were detected for rAb42 immediately after dissolu-
tion at pH 3.1. Furthermore, rAb42 neutral and acid solutions
were incubated for different times at 37C and their kinetics
of aggregation was monitored after staining with ThT.
No visible structures were detectable (data not shown) after
staining of rAb42 neutral solutions even after 4 days of
incubation, consistent with previously reported results (17).
In contrast, by monitoring rAb42 acid solutions at different
times, larger and larger structures appeared until the
formation of large aggregates of dimensions up to 20 mm
(Fig. 1 B).
Characterization of rAb42 oligomers and ﬁbrillar
aggregates before incubation in cells
For all of the biological assays reported in this work, we used
two different forms of rAb421), oligomers of rAb42
prepared by dissolving the peptide at physiological pH;
and 2), large fibrillar aggregates obtained by incubation in
an acidic solution of rAb42 for 4 days at 37C to simulate
the two different conditions of having either small oligomers
or amyloid plaques in the extracellular space. To monitor the
toxic effects on LAN5 cellular growth, the two different
solutions of rAb42 were diluted in the physiological cellular
medium. With the aim to control which forms of rAb42 were
present under the two different pH conditions, DLS was
measured at 15C to obtain the distribution of rAb42 species
(Fig. 2) from analysis of the intensity autocorrelation func-
tions. As expected from previous studies (17), the dominant
species at physiological pH are oligomers of dimensions
<10 nm, whereas larger aggregates with larger dimensions
(up to micrometers) are dominant in the acidic solutions
(Fig. 2) (hereafter we shall indicate as oligomers a mixture
of monomers and small oligomers slightly contaminated by
a tiny amount of aggregates, and as aggregates a mixture
FIGURE 2 Distribution functions of the z-averaged hydrodynamic radii
P(Rh) obtained from the analysis of the g2(t) measured for the solution of
rAb42 at pH 7.2 (broken line) and pH 3.1 (continuous line) at T ¼ 15C.
To obtain large fibrillar aggregates, the solution at pH 3.1 was incubated
at T ¼ 37C for 4 days as described in the text.of larger aggregates, from tens of nanometers to tens of
micrometers). The two solutions were then diluted in
RPMI (without phenol red to avoid absorption phenomena
in the scattering experiments), a medium that mimics the
environment of cellular growth. SLS and DLS were simulta-
neously measured for 4 h. The weight-averaged molecular
mass after dilution was estimated from the Rayleigh ratio
for both samples (Fig. 3), resulting in 25 KDa (consistent
with a pentamer) for the solution made at pH 7.2, and
23 MDa for the one obtained by diluting the sample previ-
ously aggregated at acid pH. In the latter case the form factor
was calculated using a rod-like model and assuming an
average particle dimension of ~100 nm, P(q ¼ 22.3mm1,
R ¼ 100 nm) z 0.8 (18,19). Although this is a rough esti-
mate, it confirms the dominant presence of large aggregates
of rAb42 starting from the sample at low pH and of oligo-
mers diluting the solution at neutral pH. Whereas the first
appears stable, a mild time dependence of the oligomer
dimensions is noticed in the second, suggesting that the
different milieu promotes a slightly different species distri-
bution. After dilution the peptide concentration drops to
20 mM, with a subsequent decrease of the SLS intensity.
Therefore, since the scattered intensity did not show relevant
changes (Fig. 3), we chose to analyze for both samples an
intensity autocorrelation function averaged for 3.5 h after
30 min from dilution, to give more reliability to the size
distributions obtained after dilution. The intensity distribu-
tion of the hydrodynamic radii corresponding to the solution
of fibrillar aggregates diluted in RPMI shows three distinct
populations (Fig. 4 A): large oligomers of tens of nanome-
ters, aggregates of hundreds of nanometers, and larger
species of dimensions up to tens of micrometers. The
average hydrodynamic radius as calculated from the average
diffusion coefficient of the distribution ranges from 253 nm
before dilution to 234 nm after dilution, pointing to a slight
decrease in dimensions due to dilution. The distribution of
FIGURE 3 Time evolution of both the Rayleigh ratio at 90 (left y axis)
and the weight-averaged molecular mass (right y axis), during incubation
at T ¼ 37C. Oligomers prepared at pH 7.2 (broken line) and aggregates
prepared at pH 3.1 (continuous line), immediately after dilution to 20 mM
in RPMI.Biophysical Journal 96(10) 4200–4211
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omers after dilution (Fig. 4 B) indicates species with dimen-
sions on the order of nanometers and the presence of a small
amount of aggregates with diameters ranging from hundreds
of nanometers to a few micrometers. The average hydrody-
namic radius of the distribution increases from 4 nm to
15 nm with dilution. This effect could account for the
marginal intensity increase observed in the first half hour
(Fig. 3). After dilution (Fig. 4 B), although the contribution
from the monomer-oligomers species accounts for only 5%
of the total scattered intensity (as can be estimated by the
area underneath the corresponding band), this has to be
considered as the dominant species in terms of weight
concentration and, even more, of number concentration
(see inset of Fig. 4 B). In fact, by assuming a dependence
M2w
M1w
¼
h
R2h
R1
h
i2
(15) and an intensity contribution of A1 ¼ 5%
and A2 ¼ 95% arising from species of dimensions of 1 and
100 nm, respectively, we estimated that the ratio of the
number concentrations n2n1 ¼
h
M1w
M2w
i2
P1A2
P2A1
y2:5 107, consid-
ering P1(q ¼ 22.3mm1) ¼ 1 and for the larger species the
form factor P2(q ¼ 22.3 mm1) z 0.8, calculated using
a rod-like model (18,19). We can therefore conclude, as
shown in the number distributions reported in the insets of
Fig. 4, that after dilution in RPMI the species in solution
are a heterogeneous mixture of large oligomers and aggre-
gates of hundreds of nanometers (Fig. 4 A, inset) in the
sample prepared at pH 3.1, and mainly monomers and small
oligomers (Fig. 4 B, inset) in the samples prepared at pH 7.2.
A B
FIGURE 4 Distribution functions of the z-averaged hydrodynamic radii
P(Rh), corresponding to the solution of rAb42 at pH 3.1 (A) before (contin-
uous line) and after (broken line) dilution in RPMI, and at pH 7.2 (B) before
(continuous line) and after (broken line) dilution in RPMI. For both solutions
diluted in RPMI, to improve the signal/noise ratio, the analysis was
performed on the intensity autocorrelation functions obtained by averaging
data from 30 min to 4 h. In the insets the number distribution of the hydro-
dynamic radii, Pn(Rh), is reported for the two solutions prepared at pH
3.1 (A) and pH 7.2 (B) after dilution in RPMI.Biophysical Journal 96(10) 4200–4211This analysis, together with the estimate of the weight-aver-
aged molecular mass and the average hydrodynamic radius
after dilution, strongly indicates that the sample prepared at
physiologic pH contains small oligomers and a quite small
amount of aggregates of dimensions in the range 100 nm–
1mm. Moreover, the sample prepared at acid pH appears quite
heterogeneous, with the smallest species being at least 10 times
larger than the small oligomers, which are mainly present in the
former solution. Furthermore, larger species (hundreds of
nanometers) are significantly present in the latter solution.
Concerning the largest aggregates (larger than micrometers)
detected in this sample, the relative amount can be underesti-
mated by the experimental approach used here.
Visualization of the aggregates by SEM
To examine the size and shape of the aggregates formed in
acid condition, SEM was performed on the sample incubated
for 4 days at T¼ 37C (two representative areas of the obser-
vation field are shown in Fig. 5, A and B). The SEM analysis
revealed aggregates with an elongated morphology and in
some cases a thread-like motif, with a helical twist typical
of amyloid fibrillar superstructures (see Fig. 5 B). The aggre-
gates ranged in length from hundreds of nanometers to a few
micrometers, according to both the light scattering and the
fluorescence microscopy results, in agreement with the
model reported for the Ab40 aggregates formed at the late
stage of thermal aggregation (16).
In summary, for all of the biological assays we used two
extreme conditions: 1), the rAb42 neutral solution soon after
dissolution, containing mainly small oligomers; and 2),
the rAb42 acid solution after 4 days of incubation, contain-
ing large fibrillar aggregates to simulate separately the two
conditions of having in the extracellular space small oligo-
mers or amyloid plaques that interfere with the cellular
membrane in different ways.
rAb42 binds speciﬁc cell surface sites
We then ascertained whether the recombinant peptide is able
to bind to one or more specific cellular surface sites that
FIGURE 5 SEM images of rAb42 aggregates formed at pH 3.1 after
4 days’ incubation. (A) A representative overview of aggregates. (B) A
zoom of a single aggregate, captured in a different observation field.
Apoptosis in Ab-Treated Cells 4205might potentially activate the toxic downstream pathway.
LAN5 neuroblastoma cells were incubated with a solution
containing rAb42 fibrillar aggregates, and after cell fixation
the rAb42 species were localized using anti-His fluorescent
antibodies (Fig. 6 A). Moresover, to localize APP antigen
on the utilized cell line, LAN5 cells were incubated with
human anti-Ab antibodies (Fig. 6 C). By immunohistochem-
istry, a punctuate staining was detected both on the surface of
the cellular body and on the neurites of treated LAN5 cells,
suggesting that rAb42 probably binds to some membrane
protein or lipids, and that the employed cultures are a valid
model system to simulate in vivo pathological conditions
(Fig. 6, A and B). Comparable staining was detected for
LAN5 cells incubated with anti-Ab antibodies (Fig. 6, C
and D).
Toxic effect of rAb42 on human neuroblastoma
LAN5 cells
We previously demonstrated in P. lividus embryos (17) that
oligomers are more toxic than larger aggregates. To analyze
whether this difference is maintained in mammalian cells,
we used human neuroblastoma LAN5 cells for viability
assays. In each experiment the different species in solution
(oligomers or fibrillar aggregates) were monitored by light
scattering. LAN5 cells were incubated with different concen-
trations of either aggregates at pH 3.1 (Fig. 7 B) or oligomers
at pH 7.2 (Fig. 7 D). After 5 h the morphological effects with
FIGURE 6 Recombinant Ab42 binds to the neuron cell surface and shows
the same punctuate staining of APP. Immunohistochemistry of LAN5 neuro-
blastoma cells without or with treatment of rAb42 and incubation with anti-
His (A) or with anti-b-amyloid (B), respectively. (C and D) bright field of
images in A and B. Bar: 10 mm.respect to the corresponding controls (Fig. 7, A and C) were
observed. Neurons at various stages of degeneration were
observed (representative images are shown in Fig. 7).
Morphological changes resulted in a reduction of the cellular
body, neurites, and neuronal cell number.
rAb42 oligomers and ﬁbrillar aggregates have
a different concentration and time dependence
The viability of LAN5 cells was evaluated by means of the
MTS assay, using increasing amounts of either oligomers
or aggregates. This assay gave results consistent with the
observed morphological changes: after 5 h of treatment
with aggregates or oligomers, we obtained a vitality decrease
for increasing amounts of peptide. At the same concentra-
tions, a major reduction for the oligomers treatment was
always detected (IC50, 11 mM for oligomers and 17 mM
for aggregates) (Fig. 8 A). Furthermore, when we used the
15 mM peptide concentration of either oligomers or aggre-
gates, and incubated the LAN5 cells for 5 and 24 h
(Fig. 8 B), the MTS assays revealed a time-dependent effect
and a higher toxicity for the oligomers.
rAb42 oligomers and ﬁbrillar aggregates
induce apoptosis
Cells undergoing apoptosis are known to display morpholog-
ical characteristics, including cytoplasm shrinkage, plasma
membrane blebbing, chromatin condensation, and nuclear
fragmentation (20). When we treated the cells with rAb42
oligomers and aggregates, we detected morphological
features in the surviving cells that were similar to the hall-
marks described for apoptosis (Fig. 9). Furthermore, a drastic
FIGURE 7 rAb42 oligomers and fibrillar aggregates produce morpholog-
ical changes in LAN5 neuroblastoma cells. Differential interference contrast
image of LAN5 cells (A) treated with pH 3.1 buffer, (B) incubated with
30 mM rAb42 aggregates, (C) treated with pH 7 buffer, and (D) incubated with
30 mM rAb42 oligomers. The incubation lasted 5 h in each case. Bar: 10 mm.Biophysical Journal 96(10) 4200–4211
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cells treated with oligomers, in which granules similar to
apoptotic bodies were observable. To better investigate this
effect, LAN5 cells were submitted to the TUNEL assay after
treatment with oligomers and aggregates for 5 h. An intense
nuclear staining is visible in the cells treated with rAb42 in
both forms (Fig. 9, B and C), whereas no staining is detect-
able in untreated cells (Fig. 9 A). This result was confirmed
by Hoechst 33258 staining of the nuclei. Intensive blue stain-
ing revealed the presence of DNA nicks (Fig. 9, E and F),
indicating that the observed pattern of rAb42 degeneration
is consistent with an apoptotic pathway.
rAb42 oligomers and ﬁbrillar aggregates activate
two different apoptotic pathways
Proteolytic enzymes of the caspase family play a central role
in initiating and sustaining the events that result in apoptotic
cell death. In some forms of apoptosis, the extrinsic apoptotic
pathway is initiated by activation of caspase 8 after death
receptor ligation; in others, activation of the intrinsic
apoptotic pathway is initiated by signaling molecules re-
cruited by mitochondria that produce release of cytochrome
c from the mitochondrial matrix to cytoplasm and activation
FIGURE 8 Dose and time dependence toxicity of aggregates and oligo-
mers. Neuroblastoma LAN5 cells were incubated with oligomers and
fibrillar aggregates separately at different doses and times and submitted,
together with untreated cells or pH 3.1 or pH 7.2 buffer-treated cells as
control, to viability MTS assays. (A) Percentage of viability after 5 h incu-
bation with 3.75 mM, 7.5 mM, 15 mM, or 30 mM of aggregates and oligo-
mers, compared with control. (B) Percentage of viability after incubation
for 5 and 24 h with 15 mM of aggregates and oligomers, compared with
control. The blank control value was subtracted from each. The data are
the mean  SD of three separate experiments, normalized with respect to
control.Biophysical Journal 96(10) 4200–4211of the caspase 9 (20). Both of these pathways are able to acti-
vate the executrix caspase 3 that is involved in the death
process. To identify which pathway is involved in rAb42-
induced apoptosis and to ascertain whether the difference
in toxicity between oligomers and fibrillar aggregates could
be due to activation of different apoptotic pathways, we per-
formed caspase 8 and caspase 9 luminometric assays. LAN5
cells treated with oligomers and aggregates were subjected to
both caspase 8 and 9 assays. A caspase activator was
employed as control. Cells treated with aggregates showed
a high activation of caspase 8 (Fig. 10 A) and a negligible
activation of caspase 9 with respect to the control
(Fig. 10 B), whereas cells treated with oligomers showed
some activation of caspase 8 (Fig. 10 A) and a major activa-
tion of caspase 9 (Fig. 10 B). LAN5 cells treated as described
above were employed for the caspase 3 assay and, as
expected, a significant increase of the caspase 3 activity
was detected (Fig. 10 C). Additionally, the caspase activa-
tion, when it occurred, was inhibited by the treatment of
caspase inhibitor Z-VAD-FMK (Fig. 10, A–C).
rAb42 toxic effect is recovered by caspase
inhibitor
To ascertain whether neurotoxicity is due to induction of
apoptosis, we examined the effect of a caspase inhibitor on
LAN5 cells treated with oligomers and aggregates. Oligo-
mers or aggregates were added together with the caspase
inhibitor Z-VAD-FMK to LAN5 cultures. The toxicity was
determined by means of the MTS assay 24 h after incubation.
Oligomer or aggregate toxicity was reduced by ~50% with
respect to the treated cultures, indicating that the drug devel-
oped a protective effect, and confirming that the neurodegen-
eration is due to caspase activation (Fig. 11).
Oligomers induce release of cytochrome
c into the cytosol
It is known that activation of the intrinsic apoptotic pathway
results in loss of mitochondrial membrane integrity and
release of cytochrome c in the cytosol. To confirm that olig-
omers activate the apoptotic mitochondrial pathway, cyto-
solic and mitochondrial extracts from the control and
LAN5 cells treated with oligomers and aggregates were
separated and analyzed by Western blot. In control untreated
cells, cytochrome c and actin were exclusively present in the
mitochondrial or cytosolic fractions, respectively. In olig-
omer-treated cells, a decrease of the mitochondrial pool of
cytochrome c was detected, whereas a significant amount
of cytochrome c was present in the cytosol (Fig. 12). This
is consistent with caspase 9 activation by the oligomers.
Furthermore, in the aggregate-treated cells, the major part
of cytochrome c is present in the mitochondrial fraction
and a light band is present in the cytosol, probably due to
the presence of a tiny amount of oligomers in the aggregates
solution.
Apoptosis in Ab-Treated Cells 4207FIGURE 9 Oligomers and aggregates activate apoptosis.
LAN5 untreated cells as control (A and F) or pH 3.1
(B and G) or pH 7.2 (C and H) buffers treated or treated
with fibrillar aggregates (D and I) or oligomers (E and
L), were fixed and submitted to TUNEL assay (A–E). Frag-
mentation of nuclei was evidenced by Hoechst 33258 stain-
ing (F–I and L). Bar: 20 mm.DISCUSSION
This study indicates that exposure of cultured neuroblastoma
LAN5 cells to both oligomers and fibrillar aggregates of
rAb42 induces degeneration and cell death via an apoptotic
pathway. We provide evidence that the two species induce
degeneration through two different apoptotic pathways.
The use of well-characterized oligomers or aggregates
formed starting from a recombinant peptide in vitro permitted
us to simulate the pathophysiological effects that occur
in vivo. The experimental approach of using a recombinant
Ab-peptide, with or without amino acids mutation, was em-
ployed to correlate structure and biological activity (21). We
determined the most abundant molecular species present in
solution under different conditions and ascertained that theydid not aggregate and/or dissolve under dilution in RPMI
medium during the experiments of cellular growth. Moreover,
by using immunological and microscopy techniques we were
able to ascertain that for the biological assay, oligomers and
large fibrillar aggregates were separately utilized. As described
above, the so-called oligomers sample is actually a solution
rich in small oligomers, whereas the so-called fibrillar aggre-
gates sample is a heterogeneous solution containing aggre-
gates with dimensions ranging from tens of nanometers to
micrometers. Furthermore, we used LAN5 neuroblastoma
cell lines that, as shown by immunohistochemistry, express
APP antigen on their cell surface and are able to bind rAb42.
The first relevant difference detected between oligomers
and fibrillar aggregates was that oligomers produce anBiophysical Journal 96(10) 4200–4211
4208 Picone et al.enhanced degeneration as well as cell death with respect to
aggregates. This could be related to the possibility that
diffusible oligomers can pass through the membrane and
FIGURE 10 Oligomers and fibrillar aggregates activate different path-
ways of apoptosis. LAN5 cells were treated with aggregates, oligomers, or
a caspase activator, without and with Z-VAD-FMK and submitted to
caspase 8 (A), caspase 9 (B), or caspase 3 (C) luminescent assays. Inhibition
of caspase 8 (A), 9 (B), or 3 (C) activation was observed after incubation of
LAN5 cells with oligomers or aggregates or caspase activator plus z-VAD-
fmk. Untreated cells or pH 3.1 or pH 7.2 buffer-treated cells were used as
controls. On the left the relative light units are indicated. The blank control
values were subtracted from each. The data are the mean SD of three sepa-
rate experiments, normalized with respect to the control.Biophysical Journal 96(10) 4200–4211enter into the intracellular space. Biophysical and modeling
studies have demonstrated the ability of Ab to interact
with a lipid bilayer because of its obliquity and hydropho-
bicity (22,23). Moreover, some evidence indicates that extra-
cellular Ab contributes to the intracellular pool of Ab, and
this internalization occurs via an endocytic pathway
involving caveolae/lipid rafts (24).
Neuronal cultures exposed to rAb42 exhibited DNA frag-
mentation and maintained cellular membrane integrity until
the cells died. By using different caspase assays, we detected
that the oligomers and fibrillar aggregates induced degener-
ation through two different apoptotic pathways. Aggregates
are able to activate caspase 8 almost exclusively, whereas
oligomers activate both caspase 8 and caspase 9 (although
mainly caspase 9). This effect can be reversed by a caspase
inhibitor that is also able to rescue a significant portion of
cell death. The absence of caspase 9 activation by the aggre-
gates suggests that these species are unable to activate an
internal degenerative pathway. The evidence of cytochrome
c release into the cytosol when cells were exposed to the
oligomers agrees with caspase 9 activation, and both results
suggest that oligomers can enter into the intraneuronal space.
We speculate that aggregates could mimic the extracel-
lular plaques that perturb the cell membrane and directly or
indirectly activate a death receptor, inducing an apoptotic
extrinsic pathway through caspase 8 activation. Oligomers
could mimic the diffusible oligomers that cross the neuron
membrane and enter into the intracellular environment,
where they could promote cellular mechanisms leading to
activation of the apoptotic intrinsic pathway upon caspase
9-mediated signaling (Fig. 13). Furthermore, oligomers are
able to activate, albeit to a minor extent, caspase 8, and
this could be due to the little fraction of larger aggregates
detected by light scattering in the sample at pH 7. However,
we cannot exclude the possibility that small oligomer species
themselves could attach to neuron surface-specific binding
FIGURE 11 Toxicity produced by oligomers and fibrillar aggregates
is reduced by the caspase inhibitor. LAN5 cells cultured in the presence
of oligomers alone or with z-VAD-fmk, and with aggregates alone or with
z-VAD-fmk and submitted to viability MTS assay. Untreated cells or pH
3.1 or pH 7.2 buffer-treated cells were used as controls. The corresponding
blank control value was subtracted from each. The data are the mean  SD
of three separate experiments, normalized with respect to the control.
Apoptosis in Ab-Treated Cells 4209sites and seed the aggregation process similarly to what
occurs during pathology. Moreover, it has been demon-
strated that Ab aggregates interact with their precursor and
this leads to a toxic gain of function, possibly by inducing
an APP conformational change that triggers cell death
(25). Having detected localization of both rAb42 and APP
on the cell surface, we cannot exclude the possibility that
rAb42 was bound to its precursor to induce neurotoxicity
in our in vitro experimental model. However, evidence indi-
cates that monomeric and fibrillar forms of Ab have the
ability to bind to different membrane proteins, and some of
these have been identified (26–28) Interactions between
Ab and one or more of these membrane proteins or receptors
could directly or indirectly activate the apoptotic process, as
demonstrated for receptor for advanced glycation end prod-
ucts, and may also contribute to fibrillogenesis (29,30).
The ability to bind to different membrane proteins is in
agreement with results obtained in previous studies in which
D- and L-enantiomers of Ab peptides were utilized. It was
FIGURE 12 Cytochrome c is released in oligomer-treated LAN5 cells.
Western blot of proteins extracted from mitochondrial (M) and cytosolic
(C) fractions of LAN5 cells untreated or pH 3.1 or pH 7.2 buffer-treated cells
or treated with oligomers or aggregates and incubated with anti-cytochrome
c or anti-b-actin as control.demonstrated that fibril toxicity was independent of the
classical stereoisomeric specific ligand-receptor interaction,
whereas fibril conformation, depending on its primary
sequence, was a critical feature (31). A possible mechanism
is that Ab aggregates act as a membrane perturbant that alters
the bilayer lipids and membrane-bound proteins or receptors,
inducing activation of the cell death pathway (31).
Involvement of the mitochondrial path could be an expla-
nation of the major toxicity of oligomers with respect to
aggregates. Mitochondria are pivotal in controlling cell life
and death (32). Perturbations in the physiological function
of mitochondria inevitably disturb cell function and may
initiate cell death. These are significant phenomena in the
pathogenesis of a number of neurodegenerative disorders,
including AD. Moreover, other evidence indicates that
a mechanism of Ab toxicity arises from its interaction with
a mitochondrial target such as Ab-binding alcohol dehydro-
genase (33–35). However, it is known that the mitochondrial
path is not the only source of intracellular toxicity. Indeed,
intracellular Ab is able to activate the intrinsic ER stress-
induced apoptosis mediated by caspase 12 (36).
Furthermore, the possibility that different pathways are
activated by the same sources is not an atypical condition;
indeed, similar results were obtained by studies with air
pollution particulate matter on lung epithelial cells (L132)
(37). In that system, apoptosis activation was demonstrated
both by TNF-a induced and by mitochondrial pathway.
FIGURE 13 A sketched summary of the different actions by oligomers
and fibrillar aggregates in LAN5 cell apoptosis activation. Aggregates,
disturbing and/or obstructing the cellular membrane, activate the extrinsic
apoptotic pathway upon caspase 8 and subsequently caspase 3 mediated
signaling. Oligomers can induce apoptosis by caspase 8 activation, but prin-
cipally promote cell stress, inducing the release of mitochondrial cyto-
chrome c and activation of caspase 9 and subsequently caspase 3.Biophysical Journal 96(10) 4200–4211
4210 Picone et al.However, different studies have implicated other known
caspases in Ab toxicity, and it has been demonstrated that
activity by caspases 8 and 9 is required for APP cleavage
and C-terminal peptide C31 generation, which are also
involved in cell death (38,39).
In conclusion, the different amyloid species analyzed here
cause neurotoxicity by distinct apoptotic mechanisms that
take place in different parts of the cell. The evidence suggests
that structural differences between Ab oligomers and larger
fibrillar aggregates may influence receptor-binding activity
or the internalization mechanism, and promote activation
of an extrinsic or intrinsic apoptotic pathway.
Finally, although activation of two different pathways is
only a first step in establishing the major or minor toxicity
of small oligomers with respect to larger species, the finding
that pathology may be provoked by altered states of meta-
bolic equilibrium may help in the development of new
methods for early diagnosis, as well as new therapeutic strat-
egies. In this context, progress in the emerging field of
biomedical research called mitochondrial medicine, which
involves the development of mitochondrial drugs and their
delivery systems, could also lead to novel pharmacological
treatments (40–42).
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